What a hard hitting fluff piece of a pod cast talking about the treatment business. CEO generally claims they have aggressive growth plans for 2023 after a successful 2022. Nothing about how they will support the regulation "A" offering. Nothing about the potential for a reverse split. Nothing about the crushing debt. Complete promo fluff piece with no trading the last 5 hours of the day.
2022 saw over $4 million in debt defaults and a huge Leonite note that was exchanged for the additional Labrys defaulted debt. On March 1st the $745K Leonite note will be in default with the 24% default interest calculated back to day one.
2023 will be the year for selling shares and dealing with debt holders and they won't get that done without a reverse split in my opinion.
Market Data 
Markets 
AI
